In patients with gastrointestinal cancers treated with fluoropyrimidine-based chemotherapy agents, better overall survival at 1 year offsets a small increase in their risk of CV events, new data ...

It gained approval as a single agent for treating adults with unresectable or metastatic oesophageal squamous cell carcinoma following previous systemic chemotherapy which excluded PD-L1 inhibitor ...

FDA has cleared an investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions. Patient ...

The dose of paclitaxel used in the new approach was 16-fold lower than that typically used in free paclitaxel, but with similar efficacy.

“Also, systemic chemosensitization may not be as ... even after propensity score matching, adjuvant chemotherapy did not demonstrate any survival benefit in this subgroup.

Genmab (GMAB) announced that the European Commission has granted marketing authorization for TIVDAK, an antibody-drug conjugate, as monotherapy ...

Biosciences’ collaboration partner, PeriNess has entered into a Clinical Study Agreement to support an exploratory clinical ...